🔗 Share this article

While the US proceeds with historic changes to its immunization schedules, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, a Danish American sports medicine doctor and public health researcher who rose to prominence by questioning coronavirus shots in the global health crisis and has concentrated on possible deaths following Covid immunization in her recent time at the FDA.

Scheduled Changes to Pediatric Vaccine Program

Health officials had intended to announce sweeping revisions to the pediatric vaccination calendar earlier this month, synchronizing the US with the Danish vaccine program, sources say – a substantial departure that would put the US out of step with much of the global community with insufficient data for benefit. The announcement has been postponed until the coming year.

Instead of the top vaccines chief, Dr. Høeg is listed to present at the event. She was newly appointed acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to lead the division this calendar year.

Consolidating Power at the Regulatory Body

This interim role may indicate a closer partnership between the pharmaceutical and biologics divisions as Høeg and Prasad consolidate power at the regulatory agency – and it signals a increased emphasis upon rolling back long-standing immunizations at the FDA.

The new acting director has frequently advocated for ending specific childhood immunization guidelines in the US so as to align more in line with the Danish model, a nation with nationalized medicine and a citizenry about the size of the state of Wisconsin.

So far statements, she has continued to focus on vaccination policy – traditionally the responsibility of Prasad, director of the FDA’s vaccine center – instead of medication approval.

Doubts Over Background

Dr. Høeg has no obvious experience in medication creation, regulation or administrative roles, which has been customary for previous heads of the CBER. She has served at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She appears not to have the necessary background” for running the CDER, said Dr. Jonathan Howard. “She has not conducted a randomized controlled trial. She is not versed in leading a major agency. She is not an expert in drug approvals.”

Past heads of the center would “grasp regulatory frameworks and the research of medication creation”, noted Dr. Janet Woodcock. “Objectively, she doesn’t have the type of experience that prior appointees who headed the center have had.”

This division has an vast workload at the FDA, she emphasized.

“The public just pays attention on the innovative therapies, but the generic program approves numerous generic drugs. There is also a biologic copycat branch, over-the-counter program and other areas, and all of those must be managed,” Dr. Woodcock said. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial administrative element to the position, which supervises over 5,000 employees. “It’s a huge management job, if you execute it properly,” the former official added.

Response and Contentious Policies

In response to questions about Dr. Høeg's qualifications and whether this selection represents more teamwork among regulatory chiefs on vaccines, a spokesperson responded that the “inquiries stem from inaccurate assumptions”.

“Her resume matches the functions of her position,” the representative explained, pointing to the months Dr. Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computational safety modeling and immunization monitoring”.

In her interim role, Høeg assumes responsibility for the agency head's new priority voucher program, a controversial one-day medication authorization process that reportedly worried her former heads. “How are these drugs being picked for this expedited pathway? Who takes the decisions?” Howard asked. “There’s a lot of secrecy happening at the regulatory body right now.”

Overall, he stated, “the agency looks to be trending towards laxer oversight of pharmaceuticals, except for immunizations.”

Established Past Work on Immunizations

Regarding vaccines, Høeg has a clearer, if concerning, track record, some experts said. She authored a research paper using unconfirmed public submissions to estimate the frequency of myocarditis following COVID-19 immunization. She consulted for the Florida surgeon general Joseph Ladapo, who allegedly have altered data to suggest COVID-19 vaccines are riskier than they are.

Among her “wish list” for the incoming government encompassed revising rules for recently developed shots and ending “unnecessary” vaccines, she stated post-election on a online show. At the agency, Høeg has according to sources suggested barring young men from obtaining Covid vaccinations.

“She’s an all-around true believer who begins with her preconceived notions and tailors the evidence to fit the science in a highly deceptive, dishonest fashion,” Howard said.

Consolidating Power and a “Push for Payback”

Dr. Høeg became part of fellow contrarians, {like|